Skip to main content
SpringerLink
Log in

Palonosetron: profile report

  • Drugs and Profile Reports
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. 1 The use of trade names is for product identification purposes only and does not imply endorsement.

References

  1. Siddiqui MAA, Scott LJ. Palonosetron. Drugs 2004: 64(10): 1125–32

    Article  PubMed  CAS  Google Scholar 

  2. Labianca RM. Palonosetron: a viewpoint. Drugs 2004: 64(10): 1133

    Article  Google Scholar 

  3. Tonini G. Palonosetron: a viewpoint. Drugs 2004: 64(10): 1134

    Article  Google Scholar 

  4. Gralla RJ, Osoba D, Kris MG, et al., for the American Society of Clinical Oncology. Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. J Clin Oncol 1999; 17(9): 2971–94

    PubMed  CAS  Google Scholar 

  5. National Cancer Institute. Physician Data Query (PDQ®) supportive care summaries (health professional version): nausea and ernesis [online]. Available from URL: http://cancer.gov/ [Accessed 2004 Apr 15]

  6. Eisenberg P, MacKintosh FR, Ritch P, et al. Efficacy, safety and pharmacokinetics of palonosetron in patients receiving highly emetogenic cisplatin-based chemotherapy: a dose-ranging clinical study. Ann Oncol 2004; 15(2): 330–7

    Article  PubMed  CAS  Google Scholar 

  7. Aloxi™ (palonosetron hydrochloride) injection, 0.25 mg/5ml [product information]. Lugeno: Helsinn Healthcare SA, 2003 Jul

  8. Piraccini G, Stolz R, Tei M, et al. Pharmacokinetic features of a novel 5-HT3 receptor antagonist: palonosetron (RS-25259-197) [abstract no. 1595]. Proc Am Soc Clin Oncol 2001; 20 Pt 1: 400a

    Google Scholar 

  9. Gatti S, Stolz R, Tei M, et al. A novel anti-emetic agent, palonosetron: evidence from phase I trials [poster]. Multinational Association of Supportive Care in Cancer (MASCC)/International Society of Oral Oncology (ISOO) 13th Annual International Symposium on Supportive Care in Cancer; 2001 Jun 14–16; Copenhagen

  10. Gralla R, Lichinitser M, Van Der Vegt S, et al. Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. Ann Oncol 2003 Oct; 14(10): 1570–7

    Article  PubMed  CAS  Google Scholar 

  11. Eisenberg P, Figueroa-Vadillo J, Zamora R, et al. Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron. Cancer 2003 Dec 1; 98(11): 2473–82

    Article  PubMed  CAS  Google Scholar 

  12. Aapro MS, Bertoli L, Lordick K, et al. Palonosetron (PALO) is effective in preventing acute and delayed chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC) [abstract]. Multinational Association of Supportive Care in Cancer (MASCC)/International Society for Oral Oncology (ISOO) 15th International Symposium on Supportive Care in Cancer; 2003 Jun 18–21; Berlin

  13. Helsinn Healthcare S.A. Aloxi™ (palonosetron hydrochloride) Injection NDA no. 021-372 submitted to the US FDA by Helsinn Healthcare S.A. [online]. Available from URL: http://www.fda.gov/cder [Accessed 2004 Apr 15]

  14. Cartmell AD, Ferguson S, Yanagihara R, et al. Protection against chemotherapy-induced nausea and vomiting is maintained over multiple cycles of moderately or highly emetogenic chemotherapy by palonosetron, a potent 5-HT(3) receptor antagonist [abstract no. 3041]. Proc Am Soc Clin Oncol 2003; 22: 756. Plus poster presented at the 39th Annual Meeting of the American Society of Clinical Oncology; 2003 May 31–Jun 3; Chicago

    Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Palonosetron: profile report. Drugs Ther. Perspect 20, 8–10 (2004). https://doi.org/10.2165/00042310-200420110-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00042310-200420110-00003

Keywords

Search

Navigation